We are live on ! Find out more
HAE icon

Haemonetics

295 hedge funds and large institutions have $4.63B invested in Haemonetics in 2023 Q4 according to their latest regulatory filings, with 37 funds opening new positions, 91 increasing their positions, 118 reducing their positions, and 36 closing their positions.

New
Increased
Maintained
Reduced
Closed

235% more call options, than puts

Call options by funds: $16M | Put options by funds: $4.78M

144% more capital inflows, than outflows

Capital inflows: $495M | Capital outflows: $203M

6.59% more ownership

Funds ownership: 100.03% → 106.62% (+6.6%)

3% more first-time investments, than exits

New positions opened: 37 | Existing positions closed: 36

0% less funds holding

Funds holding: 296 → 295 (-1)

23% less repeat investments, than reductions

Existing positions increased: 91 | Existing positions reduced: 118

100% less funds holding in top 10

Funds holding in top 10: 2 → 0 (-2)

Holders
295
Holders Change
-1
Holders Change %
-0.34%
% of All Funds
4.29%
Holding in Top 10
–
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-100%
% of All Funds
–
New
37
Increased
91
Reduced
118
Closed
36
Calls
$16​M
Puts
$4.78​M
Net Calls
+$11.2​M
Net Calls Change
-⁠$4.49​M

HAE Hedge Fund Activity: Q4 2023 in Review

295 of the 6,880 institutional investors tracked by Wall St. Rank reported a position in Haemonetics (HAE) for Q4 2023, worth a combined $4.63B — up 1.7% from $4.55B a quarter earlier.

Buyers outnumbered sellers: 37 funds opened new HAE positions and 36 closed out — a net gain of 1 holder — while 91 added to existing stakes and 118 trimmed.

The largest buyer was Neuberger Berman Group, adding an estimated $302M. The largest seller was Millennium Management, cutting an estimated $16M.

  • 295 institutional investors held Haemonetics (HAE) as of Q4 2023, down from 296 in Q3 2023.
  • Funds reported $4.63B of Haemonetics stock for Q4 2023, up 1.7% quarter-over-quarter.
  • 37 funds opened new Haemonetics positions in Q4 2023 and 36 closed out, a net change of +1 holder.
  • The largest Haemonetics buyer in Q4 2023 was Neuberger Berman Group, an estimated $302M added.
  • The largest Haemonetics seller in Q4 2023 was Millennium Management, an estimated $16M sold.

Based on aggregated 13F filings for Q4 2023.